On June 24, the 23rd China World Pharmaceutical Ingredients Exhibition (CPHI China 2025) opened in grand fashion at Shanghai New International Expo Centre. With the theme "Innovation, Integration, and Shared Success," the exhibition ran from June 24-26, 2025, bringing together more than 3,500 leading global brands across APIs, biotech, and other core pharmaceutical sectors.

As a global "barometer" for the pharmaceutical industry and a major hub for innovation, CPHI China showcased the latest achievements and cutting-edge technologies across the entire pharma value chain, helping shape the future development of the global healthcare industry.

(Exhibition Photo courtesy of CPHI China)

Fushine Pharmaceutical participated at booth W3B18, drawing strong interest from visitors and industry peers on the first day.

The company prepared a dedicated technical and commercial team, along with comprehensive product brochures, to provide detailed introductions to its broad product portfolio and to facilitate onsite discussion and collaboration.

Fushine Pharmaceutical at Booth W3B18

Fushine Pharmaceutical Product Portfolio

Fushine's main products include tazobactam, sultamicillin tosylate, sultamicillin, sulbactam pivalate, piperacillin, meropenem crude, sulbactam acid, iodomethyl sulbactam, tazobactam dibenzyl ester, sodium azide, benzophenone hydrazone, guanine, sitafloxacin and a wide range of other APIs and pharmaceutical intermediates.

The exhibition served as a platform for industry dialogue and global cooperation. Fushine's senior management and elite sales team engaged deeply with peers, experts, and partners, exploring opportunities and envisioning future industry development together.

Fushine Team and Our Valued Customers

Fushine Pharmacetical is one of the world's major suppliers of Sulbactam and Tazobactam series products, and one of the few companies in China with full value-chain integration—from starting materials to downstream APIs—for carbapenem-class products. The company is also a key global supplier of lopinavir-related intermediates.

Over many years, Fushine has focused on anti-infective APIs, earned a strong reputation among domestic and international customers, and achieved long-term, mutually beneficial partnerships. Today, its products are exported to dozens of countries and regions worldwide.

Fushine is actively expanding its market presence. Its subsidiary Xiangtai (Shtec) Life Science Co., Ltd., has successfully upgraded the triazole-route Tazobactam API process from non-sterile to sterile production, obtained market access qualifications, and achieved stable mass production. The carboxylic acid project, developed with independent intellectual property rights, has completed installation, commissioning, and pilot production. 

These advancements enhance the company's competitive edge in pharmaceutical manufacturing, improve profitability and risk resistance, and support Fushine's long-term high-quality growth.

As CPHI China 2025 comes to a close, Fushine Pharmaceutical extends sincere gratitude to all customers, partners, and industry peers who visited and supported our booth. We look forward to working together—capturing new opportunities, advancing global healthcare, and writing the next chapter of China's pharmaceutical story on the world stage.